"Especially for prostate cancer, some of the sexual side effects, it's tough to talk about that when you're talking to your uncle or your brother who has it," says Joseph Song, MD.
In this video, Joseph Song, MD, discusses an underappreciated aspect of prostate cancer. Song is a urologist with Georgia Urology.
It's tough to say what's underappreciated because there's so much out there now. I think multiple aspects are talked about by patients, especially when they talk to a friend or family member who's gone through it. But I think, especially for prostate cancer, some of the sexual side effects, it's tough to talk about that when you're talking to your uncle or your brother who has it. I think it can be very hard for patients to share that with friends and family. Specifically, climacturia is something that a lot of patients, even the ones we've done a lot of their homework, when I discuss that as a potential side effect, they say, "Oh my gosh, that can happen?" And we have to go through quite a lot of discussion and quite a lot of counseling, so that their partners and spouses don't think that this is something that's going to hurt them or is that an issue, because it's so common for patients to have some degree of climacturia after prostatectomy. And as we get better and better at nerve sparing, these patients are able to still achieve erections, but they're seeing this significant change in the way that their sexuality functions, and it can be pretty off putting.
This transcription was edited for clarity.
Published data show value of ClarityDX Prostate for prostate cancer screening
June 27th 2024"Using this as an adjunctive test after PSA screening will give physicians more information to help decide if their patient should undergo a prostate biopsy or not,” says M. Eric Hyndman, MD, PhD, FRCSC.
Feasibility study explores focal therapy plus radiation in prostate cancer
June 14th 2024"There's obviously a huge interest in focal therapy for prostate cancer, largely because we want to try to prevent the overtreatment of prostate cancer and also develop better approaches to deliver high-quality treatment options for patients," says Timothy D. McClure, MD.